Literature DB >> 33328705

Interventional Treatment of Hepatic Metastases from Colorectal Cancer.

Patrick D Sutphin1, Suvranu Ganguli2.   

Abstract

Modern systemic therapies provide a significant survival benefit in metastatic colorectal cancer. Despite these advances, the durability of response remains limited and nearly all patients progress on systemic treatment. Colorectal liver metastases (CLM) develop in approximately half of patients with metastatic disease and contribute to mortality in most patients. In selected patients, surgical resection of hepatic metastases prolongs survival, indicating the benefits of the targeted treatment of CLM through alternate means. Minimally invasive interventional treatments offer the promise of treating CLM in a wider range of patients than those eligible for surgical resection. Thermal ablation and intra-arterial therapies, including chemoembolization and radioembolization, are commonly used in the treatment of CLM. Each of these treatment modalities will be discussed in detail with an emphasis on the available clinical data for each interventional treatment for CLM. Thieme. All rights reserved.

Entities:  

Keywords:  ablation; colorectal cancer; colorectal liver metastases; radioembolization

Year:  2020        PMID: 33328705      PMCID: PMC7732570          DOI: 10.1055/s-0040-171919

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  52 in total

1.  Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.

Authors:  Lourens Bester; Baerbel Meteling; Nicholas Pocock; Nick Pavlakis; Terence C Chua; Akshat Saxena; David L Morris
Journal:  J Vasc Interv Radiol       Date:  2011-11-12       Impact factor: 3.464

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Colorectal cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-03-05       Impact factor: 508.702

4.  Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90.

Authors:  Michael J Magnetta; Anish Ghodadra; Steven J Lahti; Minzhi Xing; Di Zhang; Hyun S Kim
Journal:  Abdom Radiol (NY)       Date:  2017-02

5.  Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.

Authors:  Alexander Dabrowiecki; Tina Sankhla; Kaitlin Shinn; Zachary L Bercu; Mitchell Ermentrout; Walid Shaib; Kenneth Cardona; Janice Newsome; Nima Kokabi
Journal:  Cardiovasc Intervent Radiol       Date:  2020-05-04       Impact factor: 2.740

6.  Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.

Authors:  Ricarda Seidensticker; Timm Denecke; Patrick Kraus; Max Seidensticker; Konrad Mohnike; Jörg Fahlke; Erika Kettner; Bert Hildebrandt; Oliver Dudeck; Maciej Pech; Holger Amthauer; Jens Ricke
Journal:  Cardiovasc Intervent Radiol       Date:  2011-07-29       Impact factor: 2.740

7.  Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.

Authors:  Peter Gibbs; Volker Heinemann; Navesh K Sharma; Julien Taieb; Jens Ricke; Marc Peeters; Michael Findlay; Bridget Robinson; Christopher Jackson; Andrew Strickland; Val Gebski; Mark Van Buskirk; Huaqing Zhao; Guy van Hazel
Journal:  Clin Colorectal Cancer       Date:  2018-06-12       Impact factor: 4.481

8.  Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.

Authors:  Robert C G Martin; Jonathan Joshi; Ken Robbins; Dana Tomalty; Petar Bosnjakovik; Milous Derner; Radek Padr; Miloslav Rocek; Alexander Scupchenko; Cliff Tatum
Journal:  Ann Surg Oncol       Date:  2010-08-26       Impact factor: 5.344

9.  Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases.

Authors:  Waleed Shady; Elena N Petre; Efsevia Vakiani; Etay Ziv; Mithat Gonen; Karen T Brown; Nancy E Kemeny; Stephen B Solomon; David B Solit; Constantinos T Sofocleous
Journal:  Oncotarget       Date:  2017-08-02

10.  TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.

Authors:  Nikhil Chauhan; Mary F Mulcahy; Riad Salem; Al B Benson Iii; Eveline Boucher; Janet Bukovcan; David Cosgrove; Chantal Laframboise; Robert J Lewandowski; Fayaz Master; Bassel El-Rayes; Jonathan R Strosberg; Daniel Y Sze; Ricky A Sharma
Journal:  JMIR Res Protoc       Date:  2019-01-17
View more
  1 in total

1.  Association between hepatitis B virus infection and colorectal liver metastasis: a meta-analysis.

Authors:  Rongqiang Liu; Weihao Kong; Mingbin Deng; Guozhen Lin; Tianxing Dai; Linsen Ye
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.